These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38182990)

  • 21. Mutation detection and minimum inhibitory concentration determination against linezolid and clofazimine in confirmed XDR-TB clinical isolates.
    Singh K; Sharma S; Banerjee T; Gupta A; Anupurba S
    BMC Microbiol; 2022 Oct; 22(1):236. PubMed ID: 36192704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.
    Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y
    J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
    Mushtaq F; Raza SM; Ahmad A; Aslam H; Adeel A; Saleem S; Ahmad I
    PLoS One; 2023; 18(10):e0293194. PubMed ID: 37883448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    Strydom N; Gupta SV; Fox WS; Via LE; Bang H; Lee M; Eum S; Shim T; Barry CE; Zimmerman M; Dartois V; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002773. PubMed ID: 30939136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
    Wasserman S; Meintjes G; Maartens G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):901-15. PubMed ID: 27532292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linezolid Pharmacokinetics/Pharmacodynamics-Based Optimal Dosing for Multidrug-Resistant Tuberculosis.
    Zhou W; Nie W; Wang Q; Shi W; Yang Y; Li Q; Zhu H; Liu Z; Ding Y; Lu Y; Chu N
    Int J Antimicrob Agents; 2022 Jun; 59(6):106589. PubMed ID: 35405268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective study of tolerability and efficacy of linezolid in patients with multidrug-resistant tuberculosis (1998-2014).
    Ramírez-Lapausa M; Pascual Pareja JF; Carrillo Gómez R; Martínez-Prieto M; González-Ruano Pérez P; Noguerado Asensio A
    Enferm Infecc Microbiol Clin; 2016 Feb; 34(2):85-90. PubMed ID: 26015067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.
    Wasserman S; Louw G; Ramangoaela L; Barber G; Hayes C; Omar SV; Maartens G; Barry C; Song T; Meintjes G
    J Antimicrob Chemother; 2019 Aug; 74(8):2377-2384. PubMed ID: 31081017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
    Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
    Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optic neuropathy secondary to Linezolid for multidrug-resistant mycobacterial spinal tuberculosis.
    Agrawal R; Addison P; Saihan Z; Pefkianaki M; Pavesio C
    Ocul Immunol Inflamm; 2015 Feb; 23(1):90-2. PubMed ID: 24432953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India.
    Mehta S; Das M; Laxmeshwar C; Jonckheere S; Thi SS; Isaakidis P
    PLoS One; 2016; 11(9):e0162138. PubMed ID: 27611434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the impact of rifampicin on the plasma concentration of linezolid in tuberculosis co-infected patients.
    Yan P; Shi QZ; Hu YX; Zeng Y; Lu H
    Front Pharmacol; 2023; 14():1260535. PubMed ID: 38026932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
    Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
    Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
    Heinrichs MT; Drusano GL; Brown DL; Maynard MS; Sy SKB; Rand KH; Peloquin CA; Louie A; Derendorf H
    Int J Antimicrob Agents; 2019 Mar; 53(3):275-283. PubMed ID: 30385322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.
    Millard J; Pertinez H; Bonnett L; Hodel EM; Dartois V; Johnson JL; Caws M; Tiberi S; Bolhuis M; Alffenaar JC; Davies G; Sloan DJ
    J Antimicrob Chemother; 2018 Jul; 73(7):1755-1762. PubMed ID: 29584861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis.
    Wasserman S; Huo S; Ky K; Malig YN; Esmail A; Dheda K; Bacchetti P; Gerona R; Maartens G; Gandhi M; Metcalfe J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31932382
    [No Abstract]   [Full Text] [Related]  

  • 39. Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis.
    Fermeli DD; Marantos TD; Liarakos AD; Panayiotakopoulos GD; Dedes VK; Panoutsopoulos GI
    Folia Med (Plovdiv); 2020 Sep; 62(3):444-452. PubMed ID: 33009738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis.
    Alghamdi WA; Al-Shaer MH; An G; Alsultan A; Kipiani M; Barbakadze K; Mikiashvili L; Ashkin D; Griffith DE; Cegielski JP; Kempker RR; Peloquin CA
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32778547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.